Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I filtered the nuisance. His agenda is clear for all to see. Profit apart, how he can post so negatively about a company that is working so hard to bring a much needed drugs to those who need it most now and will need it in the future is incomprehensible. This is one of those times one wish Zengha is still posting here.
“So its from that afterwards selected data you/we can calculate the probabilities. What if all 10 are taken into account, the result is even worse.”
Not really Donald, we are not going forward saying we have a new drug that can treat these 10 cancer types, so how on earth are you thinking the we have to put the other 5 in the chances of successful treatment?
You really don’t like Markku do you? And you really are starting to make yourself look a bit of a fool!
Donald as I posted earlier You have changed your mind almost overnight look at your Positive posts just a month ago. The good news has been added to on Bex. RE... Bex not working In 5 patients. Diesel Is a great fuel BUT Not If you put It Into a Petrol fueled Car. Similar actions/reactions with lots of other Drugs. You know well that Good Drugs work differently In Different Patients. IMO.
Sir-Terzio: Good reflections from you. And when these % counts we also have to remember that Bex was given for a total of 10 types of cancer. From these, these 5 are then selected afterwards. So its from that afterwards selected data you/we can calculate the probabilities. What if all 10 are taken into account, the result is even worse.
That research was designed to be done this way so it’s OK, I do not blame Faron for that. But the next step is much more difficult. Then you have to choose in advance what to study and how to show the effect. It cannot be selected afterwards, as has now been done for those Printouts. In addition, a placebo group will probably join as well. As we know, the placebo group almost always perform better than not treated. This must be calculated and predicted by all. It has also been done by big pharma and we know the end result.
How do we get to a sensible offer without first further proving up what we have?
If Markku was to value us at £2-£5 billion as suggested by the deals he referred to last week, we would be currently priced at £40 - £100 per share! Clearly we need more results to get anywhere near that price, I’m willing to wait a while longer yet and it’s seems Markku is to.
No deal does not suggest there is a problem with the data, not matter how many times you try to imply it does!
If you took your vendetta against Markku off the table maybe you could see no deal might just mean Bex is progressing as planned and the longer Faron are in full control the better.
LimestOne: If you didn’t know that’s exactly what drug development is all about (calculating). Once a medicine has been shown to have enough evidence of its effectiveness and safety, it will enter the market. Before that, all you can do is calculate and predict. Faro’s situation seems worrying as the power does not convince the big pharma companies at the moment and therefore there is no sensible deal on offer. Deal in P1 or P2 is not is not uncommon as long as the data is in order.
I find it interesting that after all these years, research, articles, reviews etc. someone on this forum calculates that there isn't any benefit after all.
On the other hand your logic would imply:
60-70% of patients do not respond to Bex, of these 28% are alive after 6 months.
=> 0.6 * 0.28 = ~17%
and 0.7 * 0.28 = ~20%
83% respond to Bex treatment and are alive after 6 months.
=> 17 - 20% vs 83%
The comparison is not apples to apples anymore as an accidental banana has slipped into the equation.
The average response rate for checkpoint inhibitors is 13% , 87% non responders .
According to Farons last presentation.
So to get 30-40% isn't too shabby .
Donald T, I've lost count, are you invested at the moment or sold out.. I have the feeling you are trading this stock.. nothing wrong with that, we all have our strategies.
But do us all a favour, when you are out and want the price to drop dont come round dogging the stock. Not cool man!
"All this feigned enthusiasm is a sign that licensing went wrong in the summer" with whom did we try to get a licensing deal in the summer? Can you not accept that the results for Bex have been positive and the longer we keep full control the better?
"and now we have to get funding from investors" we are not at market yet, one way or the other we were always going to have to get funding.
"Big pharmaceutical companies are not convinced of the existing data" have you taken a poll from those who viewed the ESMO presentation, or is this based on your own negative view?
"Markku is trying to convince small investors by talking up the share price." Clutching at straws now to suggest small investors can keep the lights on.
"Yesterday’s speeches are by no means in line with today’s news" what did you feel was missing from todays news?
How much did you lose on the Vap deal...
All this feigned enthusiasm is a sign that licensing went wrong in the summer and now we have to get funding from investors. Big pharmaceutical companies are not convinced of the existing data and that is why Markku is trying to convince small investors by talking up the share price. In that way try keep the damage so small as possible. Yesterday’s speeches are by no means in line with today’s news. More and more reminiscent of vap-licensing that became a full flop.
Have you factored in the survival rates of alternative immunotherapy options...which not not very high.
Also we are currently last line, what happens when we are testing on patients that have not already been through 2, 3 or 4 rounds of other treatments first?
Finally what happens when we can identify through bio markers the DCR group?
Not everyone on DCR-group (30-40% of patients) survive. Only 83% of them. Therefore your probability to be alive after 6 month is 25-33% if you belong on DCR-group and 28% if you belong on non-DCR-group which doesn't get any help of Bex. So what's the difference of your alive probability? How would you calculated this?
If I was one of the 30 to 40% of paitents kept alive by bex I think I would be pretty happy
Bex has impact to 30-40% patients (DCR) which 83% are alive after six month. 83% of 30% is 25% and 40% of 83% is 33%. And 28% of patients not affected by Bex (non-DCR) are also alive after six months. So is there any benefit (25-33% versus 28%) after all? Or is there something what I don't understand now?